Patients with hypertension are likely to get an alternative treatment. According to Exelixis, Inc, its partner Daiichi Sankyo Company, Limited had submitted a regulatory application for esaxerenone to the Japanese Pharmaceutical and Medical Devices Agency. The identification of esaxerenone resulted from a research collaboration between Exelixis and Daiichi Sankyo. The partnership has been excellent according to Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.
He notes, “Daiichi Sankyo has been an excellent partner throughout the years, and continues to be effective in its clinical and regulatory progress.”
The discovery, development, and commercialization of novel therapies
Daiichi Sankyo’s application has been prepared from the results of phase 3 studies including ESAX-HTN. The study’s aim was to evaluate the efficacy and safety of esaxerenone versus eplerenone and particularly in patients suffering from essential hypertension in Japan. A 2012 Japan National Health and Nutrition Survey outlines that close to 43 million patients in the country suffer from hypertension. A majority of those affected are men at 60% followed by women over the age of 30 who are at 45%.
However, the discovery and the development of the novel therapies by the duo is likely to bring the numbers down. Furthermore, both Daiichi Sankyo and Exelixis have different strengths and are destined to improving the lives of a majority living with hypertension. The duo’s achievement is another milestone, which is expected to improve the business revenues for Exelixis.
Exelixis’s untapped veins in the biotech gold mine
Exelixis has been successful since it opened its doors in 1994. The oncology-focused biotechnology company has established a broad drug discovery and development platform, which it is holding together in its efforts to bring new cancer therapies to patients. It’s prudently investing in its business as it tries to maximize the potential of its pipeline. The strategy is to enhance the existing therapeutic assets with targeted business development.
In a nutshell, the company seems to have everything put together in terms of what it needs. Besides, it has been able to seal collaborative agreements, which are likely to pave way for further combinations.